At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Market Closed 10-09 16:00:00 EDT
40.98
+0.35
+0.86%
盘后40.98
+0.000.00%
19:30 EDT
High42.06Low40.29Vol1.00M
Open41.00D1 Closing40.63Amplitude4.36%
Mkt Cap3.00BTradable Cap2.53BTotal Shares73.27M
T/O41.43MT/O Rate1.62%Tradable Shares61.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

TD Cowen Remains a Buy on Enliven Therapeutics (ELVN)
TIPRANKS  ·  10-08 17:55
TD Cowen Remains a Buy on Enliven Therapeutics (ELVN)
Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial
MT Newswires Live  ·  10-07
Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial
Enliven Therapeutics Announces FDA Alignment on Enable-2 Phase 3 Trial Design for Relcobatinib (Elvn-001) in Previously Treated Chronic Myeloid Leukemia
THOMSON REUTERS  ·  10-07
Enliven Therapeutics Announces FDA Alignment on Enable-2 Phase 3 Trial Design for Relcobatinib (Elvn-001) in Previously Treated Chronic Myeloid Leukemia
Enliven Therapeutics - on Track to Initiate Enable-2 Phase 3 Trial Before Year-End 2026
THOMSON REUTERS  ·  10-07
Enliven Therapeutics - on Track to Initiate Enable-2 Phase 3 Trial Before Year-End 2026
Enliven Therapeutics Director Garland J. Scott Disposes of $606,719 in Common Shares
Reuters  ·  10-06
Enliven Therapeutics Director Garland J. Scott Disposes of $606,719 in Common Shares
Enliven initiated with an Overweight at Morgan Stanley
TIPRANKS  ·  10-02
Enliven initiated with an Overweight at Morgan Stanley
Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75
THOMSON REUTERS  ·  10-01
Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75
Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares
Reuters  ·  09-22
Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares
Enliven Therapeutics Management to Attend Morgan Stanley Global Healthcare Conference Fireside Chat
Reuters  ·  09-04
Enliven Therapeutics Management to Attend Morgan Stanley Global Healthcare Conference Fireside Chat
Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026
Reuters  ·  09-01
Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting
THOMSON REUTERS  ·  09-01
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)
TIPRANKS  ·  08-24
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)
Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17
Reuters  ·  08-20
Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17
Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62
THOMSON REUTERS  ·  08-18
Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62
Enliven initiated with an Outperform at William Blair
TIPRANKS  ·  08-18
Enliven initiated with an Outperform at William Blair
Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating
THOMSON REUTERS  ·  08-18
Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating
U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Reuters  ·  08-17
U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus
TIPRANKS  ·  08-13
Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus
Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares
Reuters  ·  08-07
Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares
Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
TIPRANKS  ·  08-06
Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)

Introduction

Company Name.
Enliven Treateutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Issue price:
--